Maryland House Bill HB1440

Maryland 2026 Regular Session

• Introduced: 2/13/26
• Refer: 2/13/26

Caption

Maryland Medical Assistance Program and Health Insurance - Coverage and Utilization Review - Drugs Reviewed by the Prescription Drug Affordability Board

Impact

The implementation of HB 1440 would significantly modify the landscape of prescription drug coverage in Maryland. It aims to ensure patients are not subjected to unnecessary bureaucratic hurdles when accessing medications deemed affordable by the Board. By restricting the ability of managed care organizations to impose additional requirements on drugs that have undergone review, the bill seeks to enhance patient care and reduce delays in receiving necessary treatments. This will likely influence the operations of health insurers and increase accountability in their coverage decisions.

Summary

House Bill 1440 focuses on the Maryland Medical Assistance Program and aims to reform how managed care organizations and other insurers handle prescription drug coverage and utilization reviews. The bill prohibits these organizations from requiring prior authorization or step therapy protocols for medications that have been evaluated by the Prescription Drug Affordability Board. This regulation is intended to streamline processes for patients and ensure access to critical medications, thus addressing affordability challenges associated with these drugs.

Contention

While supporters of HB 1440 advocate for improved access to necessary medications and reduced administrative burdens on patients and healthcare providers, there are potential points of contention regarding the oversight of managed care organizations. Critics may argue that eliminating prior authorization requirements could lead to increased costs for insurers or result in the over-prescription of drugs without appropriate management. Balancing patient access with cost controls will be essential as the bill moves through legislative processes.